Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Equity Average (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Equity Average for 2 consecutive years, with $13.6 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 29.54% to $13.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Dec 2025, down 29.54% year-over-year, with the annual reading at $26.4 million for FY2025, N/A changed from the prior year.
  • Equity Average hit $13.6 million in Q4 2025 for Xilio Therapeutics, up from -$513000.0 in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $29.6 million in Q2 2024 to a low of -$513000.0 in Q3 2025.